OTLK (Outlook Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on OTLK (Outlook Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

OTLK

Outlook Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Nov 13, 2025
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Nov 3, 2025
Outlook Therapeutics Provides Update on Type A Meeting with FDA
Sep 29, 2025
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
Sep 3, 2025
Outlook Therapeutics Requests Type A Meeting with FDA
Sep 2, 2025
FDA Rejects Outlook Therapeutics Eye Drug For Second Time
Aug 28, 2025
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
Aug 28, 2025
Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Aug 14, 2025
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
Aug 14, 2025
New Strong Buy Stocks for July 30th
Jul 30, 2025
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Jul 24, 2025
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Jul 22, 2025
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
Jul 1, 2025
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
Jun 18, 2025

Reviews